Ítem
Solo Metadatos

Tuberculosis in patientes treated with tumor necrosis factor-alpha antagonists living in an endemic area. Is the risk worthwhile?

Mostrar el registro sencillo de la publicación
dc.creatorRojas-Villarraga A.spa
dc.creatorAgudelo C.A.spa
dc.creatorPineda-Tamayo R.spa
dc.creatorPorras A.spa
dc.creatorMatute G.spa
dc.creatorAnaya, Juan-Manuelspa
dc.date.accessioned2020-05-26T00:02:52Z
dc.date.available2020-05-26T00:02:52Z
dc.date.created2007spa
dc.description.abstractTumor necrosis factor alpha antagonists (TNFA) are biological agents to treat chronic inflammatory and autoimmune diseases. However, their use is associated with an increased rate of tuberculosis, endemic mycoses, and intracellular bacterial infections. Since tuberculosis is moderately to highly endemic in Colombia, the risk of these infections in patients treated with TNFAs may be higher than previously reported in Colombia. Recently, four patients have developed tuberculosis during TNFA therapy. Tuberculosis appeared between 3 to 24 months after initiation of TFNA therapy and was independent of previous tuberculin skin test status. A review of the relevant literature and recommendations are presented as guides for surveillance and prophylaxis on a country-wide basis.eng
dc.format.mimetypeapplication/pdf
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/23535
dc.language.isoengspa
dc.relation.citationEndPage171
dc.relation.citationIssueNo. 2
dc.relation.citationStartPage159
dc.relation.citationTitleBiomedica
dc.relation.citationVolumeVol. 27
dc.relation.ispartofBiomedica, Vol.27, No.2 (2007); pp. 159-171spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-35548992792&partnerID=40&md5=68ffc0d153c9bfc5c96f456393d53c4aspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordBacteria (microorganisms)spa
dc.subject.keywordAntiinflammatory agentspa
dc.subject.keywordMonoclonaleng
dc.subject.keywordMonoclonal antibodyspa
dc.subject.keywordTumor necrosis factor alphaspa
dc.subject.keywordAdultspa
dc.subject.keywordAgedspa
dc.subject.keywordArticlespa
dc.subject.keywordAutoimmune diseasespa
dc.subject.keywordCase reportspa
dc.subject.keywordColombiaspa
dc.subject.keywordDrug antagonismspa
dc.subject.keywordFemalespa
dc.subject.keywordHumanspa
dc.subject.keywordImmunologyspa
dc.subject.keywordMalespa
dc.subject.keywordMiddle agedspa
dc.subject.keywordRisk assessmentspa
dc.subject.keywordRisk factorspa
dc.subject.keywordTuberculosisspa
dc.subject.keywordAdultspa
dc.subject.keywordAgedspa
dc.subject.keywordAnti-Inflammatory Agentsspa
dc.subject.keywordAntibodieseng
dc.subject.keywordAutoimmune Diseasesspa
dc.subject.keywordColombiaspa
dc.subject.keywordFemalespa
dc.subject.keywordHumansspa
dc.subject.keywordMalespa
dc.subject.keywordMiddle Agedspa
dc.subject.keywordRisk Assessmentspa
dc.subject.keywordRisk Factorsspa
dc.subject.keywordTuberculosisspa
dc.subject.keywordTumor Necrosis Factor-alphaspa
dc.subject.keywordColombiaspa
dc.subject.keywordEndemic diseasesspa
dc.subject.keywordTuberculosisspa
dc.subject.keywordTumor necrosis factor-alpha/immunologyspa
dc.titleTuberculosis in patientes treated with tumor necrosis factor-alpha antagonists living in an endemic area. Is the risk worthwhile?spa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Colecciones
Artículos